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ABBREVIATIONS 
ALK – Anaplastic lymphoma kinase 
BAC – Broncho alveolar carcinoma 
CNS – Central nervous system 
COPD – Chronic obstructive pulmonary disease 
CT – Chemotherapy 
EGFR – Epidermal growth factor receptor 
FDA – United States Food and Drug Administration 
GTPase – Guanosine triphosphate hydroxylase 
KRAS – V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
MDT – Multidrug therapy 
NSCLC – Non-small cell lung carcinoma 
PS – Performance status 
RT – Radiotherapy 
TKI–Tyrosine kinase inhibitor 
WHO– World Health Organization 
WT – Wild type  
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Bronchial-Pulmonary Carcinoma:  Molecular and Clinical Characterization - Histology, 
Mutations, Staging, Therapeutics and Survival 
ABSTRACT 
OBJECTIVE: Clinical characterization and therapeutic follow-up after histological typing 
and molecular pathology of Bronchial-Pulmonary Carcinoma 
MATERIAL AND METHODS: This retrospective study is supported by information 
collected from a 2011-2013 data basis provided by Instituto de Anatomia Patológica e 
Patologia Molecular of Faculty of Medicine of Coimbra, concerning histological typing and 
EGFR, KRAS and ALK mutation status in biopsies, and subsequent follow up of patients, 
treated at University Hospital of Coimbra, Instituto Português de Oncologia of Coimbra and 
Hospital of Guarda. 
RESULTS: Data corresponds to 56 patients with bronchial-pulmonary carcinoma, most 
(64.3%) of whom were male. Adenocarcinoma was the most common histological type 
(66.1%), followed by pleomorphic (8.9%), epidermoid (7.1%), adenosquamous (7.1%), large 
cell (5.4%), sarcomatoid (3.6%) and mucoepidermoid (1.8%) carcinomas. In men, the most 
common histological type was adenocarcinoma (66.7%), as well as in women (65%). The 
mean age at diagnosis was 66 years old. About 62.5% had prior history of smoking. 64.3% 
presented stage IV at diagnosis, 14.3 % IIIB, 7.1 % IIIA and the remaining 14.3% was 
classified as stage I or II.  In 29 cases patients showed mutated epidermal growth factor 
receptor, comparing with 27 biopsies wild type. About 39.3% received tyrosine kinase 
inhibitors and 32.1% were treated with chemotherapy combined with radiotherapy.     
CONCLUSIONS: The study showed higher incidence of bronchial pulmonary carcinoma in 
men. Adenocarcinoma was the most frequent histological type either in men and women. 
Smoking habit was prevalent. The majority of patients with mutated status for epidermal 
growth factor receptor received tyrosine kinase inhibitors (19). For patients wild type, 
conventional chemotherapy was applied in most cases (19) .The overall survival for patients 
carrying mutated epidermal growth factor receptor is higher, comparing with the ones wild 
type, and this result has statistical significance. Radiotherapy was used in association with 
chemotherapy or alone in palliative therapeutic measures. Most patients presented advanced 
stages at diagnosis and so curative options were applied only in few cases (11). 
Keywords: EGFR, ALK, KRAS, TKI treatment, Adenocarcinoma, Survival 
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Introduction 
According to the World Health Organization (WHO) and based on World Cancer Report 
2014, lung cancer is currently the malignant tumor with the highest mortality (1.59 million deaths) 
followed by liver (745 000 deaths), stomach (723 000 deaths), colorectal (694 000 deaths), breast 
(521 000 deaths) and esophageal (400 000 deaths) cancer. The 5 most common cancers diagnosed 
in 2012 among men were lung, prostate, colorectal, stomach, and liver cancer. Among women, 
breast, colorectal, lung, cervix, and stomach cancer had this decreasing incidence.[1] 
Smoking habit continues to be the most important risk factor for lung cancer causing 
around 70% of global lung cancer deaths.[1] 
In clinical practice, bronchial-pulmonary carcinomas are classified as small cell 
carcinoma, squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. According with 
1999/2004 classification, other less frequent histological types are adenosquamous carcinoma, 
pleomorphic carcinoma, sarcomatoid carcinoma and carcinoid tumor.[2]The actual classification 
for lung cancer, beyond establishing criteria for recognition of patterns and histological types, has 
also commitment with prognosis and predictive studies of molecular pathology that showed a 
correlation between morphology and prognosis outcome directing personalized therapy.[3] Thus, 
tumors undergo epidermal growth factor receptor (EGFR) gene analysis.  
EGFR is a transmembrane protein with cytoplasmic kinase activity that transduces 
important growth factor signaling from the extracellular milieu to the cell. More than 60% of 
epidermoid carcinoma and adenocarcinoma express EGFR and therefore, it became an important 
therapeutic target for the treatment of these tumors. Tyrosine-kinase inhibitors (TKIs) are 
particularly effective in patients whose tumors harbor activating mutations in the tyrosine kinase 
domain of the EGFR gene.[4]  So, in 2003 and 2004, gefitinib and erlotinib, respectively, were 
approved by the United States Food and Drug Administration (FDA) for advanced 
adenocarcinomas that had not responded to previous conventional chemotherapy (CT). [5] Recent 
trials have suggested that for advanced adenocarcinoma patients with EGFR mutant status, initial 
therapy with TKIs instead of conventional CT may be the best choice of treatment.[4] Thus, most 
guidelines have been updated with the consensus that an EGFR mutation is the strongest 
predictive factor for TKI treatment .[6] Therefore, mutation testing is mandatory to identify these 
patients, given that selection based only on clinical-pathologic characteristics is incomplete.[4]  
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Bronchial – Pulmonary adenocarcinomas also harbor activating mutations in the 
downstream GTPase, KRAS, and mutations in EGFR and KRAS are often mutually exclusive. 
KRAS mutations occur more frequently in lung adenocarcinomas (30%) and less frequently in the 
squamous cell carcinoma subtype (5%). Unlike EGFR mutations, which occur more frequently in 
tumors of never-smokers, the presence of a KRAS mutation cannot be predicted on the basis of 
smoking history alone.[7] Recent studies indicate that patients with mutant KRAS tumors fail to 
benefit from adjuvant CT and do not respond to EGFR inhibitors.[8] In the vast majority, KRAS 
mutations are found in tumors EGFR wild type (WT) and without ALK alterations. Therefore, 
KRAS mutation defines a distinct molecular subset of the disease.[9] 
Some tumors contain an inversion in chromosome 2 that juxtaposes the 5' end of the 
EML4 gene with the 3' end of the ALK gene, resulting in the novel fusion oncogene EML4-ALK. 
ALK fusion oncogene defines a molecular subset of tumors with distinct clinical and pathologic 
features. Patients presenting ALK rearrangement are relatively young, never or light smokers and 
diagnosed with adenocarcinoma. For those with advanced or metastatic tumors with a 
characteristic ALK fusion oncogene it is recommended initial treatment with the ALK inhibitor 
crizotinib rather than CT.[10] 
When using CT only, advanced-stage (stage IIIB or IV) tumors are treated with a double 
combination of a platinum compound (cisplatin or carboplatin) with gemcitabine, vinorelbine, or a 
taxane (paclitaxel or docetaxel) according with reference regimens.[11] 
Material and Methods 
For this retrospective study, biopsies were randomly selected and then a follow up was 
performed in order to characterize the sample. Thus, patients’ files were accessed and variables 
were selected. Gender, age, smoking habit, histological type, mutations, staging, treatment, and 
survival were analyzed. For the description of the categorical variables (gender, smoking habit, 
histological type, mutations, staging and treatment), distributions of frequencies was used. For the 
continuous or numerical variables (age), measurements of central tendency were performed. 
Overall survival was obtained using the Kaplan-Meier method. Survival stratified by mutation 
status, smoking habit and staging was also obtained. The differences among the survival curves 
were determined using the log-rank test, and the level of significance was set at 5%. The statistical 
analyses were performed using the MedCalc® program for Microsoft Partner, Application 
Development. 
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HISTOLOGICAL 
TYPE 
 
RF (%) 
 
Male/Female 
Present or Past 
smokers  – 
male/female 
 
EGFR 
 
KRAS 
 
ALK 
fusion 
STAGES 
IA IB IIA IIB IIIA IIIB IV 
Adenocarcinoma 37 (66,1%) 24/13 18/4 18 6 1 4 2 - - 3 5 23 
Pleomorphic 
carcinoma 
5 (8,9%) 2/3 2/1 3 1 1 - 1 - - 1 -   3 
Epidermoid  
carcinoma 
4 (7,1%) 4/0 4/0 2 - - - - - - - 1 3 
Adenosquamous 
carcinoma  
4 (7,1%) 2/2 2/0 1 1 - - - 1 - - 2 1 
Large cell  
carcinoma 
3 (5,4%) 2/1 2/0 3 - - - - - - - - 3 
Sarcomatoid 
carcinoma  
2 (3,6%) 2/0 2/0 1 - - - - - - - - 2 
Mucoepidermoid 
carcinoma  
1 (1,8%) 0/1 0/0 1 - - - - - - - - 1 
Table 1 – Distribution of gender, smoking habit, gene mutations and staging according to histological type 
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Fig1. Kaplan Meier overall survival curve for the entire population (mean survival time: 24.55 
months, CI 95% 18.70 – 30.40) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig2. Kaplan Meier survival curves comparing patients with EGFR mutation and EGFR wild type 
(P = 0.0486; CI 95%) 
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Fig3. Kaplan Meier survival curves comparing staging groups (mean survival time: I and II – 
52.67 months, IIIA – 32.00 moths, IIIB and IV – 16.80 months; P = 0, 0018; CI 95%) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig4. Kaplan Meier survival curves comparing 2 groups: tobacco intake and/or other risk factor 
for lung carcinoma versus non-smokers and no risk factor described (P = 0, 0869; CI 95%) 
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Results 
Data corresponds to 56 patients with lung cancer, most (64.3%) of whom were male. The 
most common histological type was adenocarcinoma (66.1%), followed by pleomorphic 
carcinoma (8.9%), epidermoid carcinoma (7.1%), adenosquamous carcinoma (7.1%), large 
cell carcinoma (5.4%), sarcomatoid carcinoma (3.6%) and mucoepidermoid carcinoma 
(1.8%). (Table 1) In men, the most common histological type was adenocarcinoma (66.7%), 
as well as in women (65%). The mean age at the moment of diagnosis was 66 years old.  
About 62.5 % had prior history of smoking, especially men (83.3%) and the most common 
histological type in smoking patients was epidermoid carcinoma (100%) and in non-smokers 
was adenocarcinoma, especially in women (60%). The EGFR mutation status (29) was not 
associated with smoking; we found 13 non-smokers and 16 smokers, presenting the mutated 
status. KRAS mutation was tested in 24 adenocarcinomas resulting 6 positive biopsies; the 
remaining tested KRAS was 4 epidermoid carcinoma with no positive result, 3 pleomorphic 
carcinoma resulting in 1 positive biopsy and also 3 adenosquamous carcinoma with 1 positive 
biopsy. ALK fusion oncogene was tested in 11 patients and was positive in 2 cases (1 
adenocarcinoma and a pleomorphic carcinoma with a component of adenocarcinoma). These 
patients were relatively young (28 and 57 years old) and received crizotinib. Concerning 
staging, 64.3% presented stage IV at the time of diagnosis, 14.3% presented stage IIIB, 7.1% 
presented stage IIIA, and the remaining 14.3% was classified as stage I or II. (Table 2) In 
65.5% of cases, patients who showed EGFR mutation received TKIs. From those with EGFR 
WT, 70.4% received conventional CT only. About 32.1% were treated with CT combined 
with radiotherapy (RT). Some (3.7%) were submitted to surgery alone or surgery 
accompanied by CT, with or without RT (19.6%).The most common patients’ complaints 
along the time where dyspnea (46.4%), cough (39.3%), the pain from metastasized bone 
cancer (37.5%), chest pain (35.7%) and blood-tinged sputum (30.4%). The overall survival 
for this population was 42.4 months. (Fig.1) 
Discussion and Conclusions 
In this study it was obtained a 1.8:1 male/female ratio for bronchial-pulmonary 
carcinoma. This result is identical to the one registered in the United States, where the lung 
carcinoma was the first cause of death in men and also became the first cause in women 
surpassing breast cancer.[12] In men we found a higher index for the use of tobacco, what can 
clearly justify this ratio. Tobacco is the major cause for lung carcinoma in as many as 90% of 
patients.[13] For never smokers, different etiology and carcinogenic processes are likely to be 
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involved, but current understanding is still limited.[14] Data in this study corresponded to 
62.5 % of present or past smokers. The risk of lung cancer declines slowly after smoking 
cessation and this long term risk explain the development of almost 50% of lung cancer cases 
in past smokers.[13] Nevertheless in some, especially women, a great percentage develops 
carcinoma and do not smoke. Therefore other causes should be described such as passive 
smoking or the occupational exposure to carcinogenic substances that are related with lung 
carcinoma, according to literature. Our data indicates that in three non-smoking patient, it was 
described occupational exposure - one patient worked in a foundry, other in plastic 
manufacturing and the third as a mechanic with car smoke exposure.  
The predisposition to develop lung tumors also seems to increase in some respiratory 
diseases such as chronic obstructive pulmonary disease, tuberculosis and in all respiratory 
diseases that curses with fibrosis.[15] In this study 3 smoking patients were diagnosed with 
chronic obstructive pulmonary disease (COPD) and one of them also had tuberculosis in the 
young age; it was too found a nonsmoking female, diagnosed with scleroderma and 
consequently pulmonary fibrosis, that developed lung carcinoma. These risk factors should be 
described and well clarified to understand the reason behind the development of the disease in 
each individual. For instance, 22 patients included in this study lived in Guarda, a region 
where the presence of radon, which is a radioactive gas produced as a result of uranium 
decay, can be present in soil, air and water and that in high concentrations is related with lung 
carcinoma; radon exposure is a well-established risk factor for lung cancer in uranium miners. 
Approximately 2-3% of lung cancers annually are estimated to be caused by radon exposure. 
Radon is associated with granites and the existence of granitic source rocks, which are rich in 
uranium crystals and are present in this area.  Has no color, taste or smell, does not react 
chemically and so it is not detectable by the senses and upon release of the soil can 
accommodate up inside houses. Household exposure to radon, however, hasn’t clearly shown 
to cause lung cancer [13] but various studies show appreciable hazards from residential radon, 
particularly for smokers and recent ex-smokers being responsible for about 2% of all deaths 
from cancer in Europe.[16]  
Asbestos is clearly defined as another carcinogenic substance that increases the risk of 
developing lung cancer by as much as 5 times; in this study in one patient, besides the 
smoking habit it was described the asbestos exposure. This can act as a synergism for the 
development of the disease and in these persons the smoking habit and the history of asbestos 
exposure approaches 80-90 times comparing with control populations.[13] Asbestos also are 
related with mesothelioma and in other case, also a smoking patient developed 
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adenocarcinoma and synchronically mesothelioma. Evidently for this case the prognosis was 
not favorable and the patient only had 5 months of living since the diagnosis was made.   
Additionally, also the radioisotope exposure, such as radioactive iodine is related with 
the increase for developing other carcinomas such as lung cancer.[17] In our study, a female 
patient, non-smoker and with no described occupational exposure, treated with radioactive 
iodine for thyroid cancer (papillary carcinoma), developed adenocarcinoma 15 years later. 
In this research, the mean age of diagnosis was 66 years old. Lung cancer occurs 
predominantly in persons aged 50-70 years; it is very low until age 39 in both sexes.[13] In 
this study it was found one smoking female patient diagnosed with adenocarcinoma at 39 
years old and one smoking male with 28 years old, also an adenocarcinoma. The probability 
for developing lung cancer reaches the peak among those older than 70 years. In this research 
19 patients were older than 70. 
The most common histological type in this study was adenocarcinoma (66.1%), as 
verified in the rest of Europe and in the United States[12], followed by pleomorphic 
carcinoma (9.1%), epidermoid carcinoma (7.1%) and adenosquamous carcinoma (7.1%). 
Others like large cells, sarcomatoid and mucoepidermoid carcinomas were less frequent. 
Adenocarcinoma arises from the bronchial mucosal glands and is the most frequent non-small 
cell lung cancer representing 35-40% of all lung cancers. It is also the subtype observed most 
commonly in persons who do not smoke.[13] Broncho alveolar carcinoma (BAC) is a distinct 
subtype of adenocarcinoma with a classic manifestation as an interstitial lung disease on chest 
radiograph. BAC keeps being controversial as considered an in situ carcinoma in WHO 
classification and then reported with metastases in some series. BAC is multifocal and often 
bilateral. However in the presence of larger lesions with a mixed non- mucinous and 
mucinous type, when desmoplastic reaction is present with acinar invasion and then related to 
lymph node metastases is no more a BAC in WHO classification but a mixed type 
adenocarcinoma.[3]It is well stated that pulmonary adenocarcinomas in women have a better 
prognosis.[3]The response to TKI-based therapy and EGFR mutations is more frequently 
found in nonsmokers, female patients, adenocarcinomas, and lung cancers showing bronchi 
alveolar features.[7] In this research concerning adenocarcinomas, 13.5% were described as 
BAC and 16.2% as mixed type adenocarcinoma. In women the adenocarcinoma is much more 
prevalent then epidermoid carcinoma and in line with this, it was registered in this study all 
the epidermoid cases in men. Women also had a higher rate of carcinoma in non-smokers 
(45%) then men (16.7%) and these facts can distinguish a group of population with 
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adenocarcinoma consisting in women and non-smokers. NSCLC in women is a growing 
health concern in Western countries. The disease is reported as a peculiar pathological and 
molecular entity: women are more affected by lung adenocarcinoma and the tumor arises 
among never or light smokers with higher frequency than in men.[18] Historically, 
epidermoid carcinoma is related with smoking habit, mostly male gender, and also here in all 
cases the patients were smokers and men.  However, differences in tobacco smoking habits 
(filters, light tobacco, cigarettes) appear to favor the development of distal bronchiolar and 
alveolar carcinogenesis at the expense of proximal squamous cell carcinoma [5]what justifies 
the increasing of adenocarcinoma surpassing epidermoid carcinoma in the last years. 
Concerning mutations, EGFR mutation is found in almost half of the biopsies, which 
is verified also in numerous series [19]; according to these no prior history of smoking is 
common as well as the female gender. In this study adenocarcinomas with EGFR mutation 
are about 48.6% but the mutation was also found in the other histological types.  Among 
adenocarcinomas, mutations were mostly associated with nonsmokers (55.6%) rather than 
smokers. So, decreasing mutation rates with increasing direct tobacco exposure was observed. 
Therefore, EGFR mutations were prevalent in lung adenocarcinoma suggesting that it plays 
an increasing oncogenic role with decreasing direct tobacco damage.[14] 
For KRAS, mutations are found predominantly in adenocarcinomas. In this study 34 
biopsies were performed and 8 of them where positive, 6 in adenocarcinomas and 1 in a 
pleomorphic carcinoma and the other in adenosquamous carcinoma. According with 
literature, KRAS is less common then EGFR, being present in 25% of cases and also in this 
characterization only 23% for tested KRAS was mutated. KRAS when occurs together with 
EGFR muted, appears to confer some resistance to TKIs. The 37 cases of mutated EGFR and 
KRAS occurred in mutually exclusive tumors, in the majority of the biopsies; only in 3 cases 
they occurred together. In these cases, comparing with those with associated WT KRAS and 
mutated EGFR, we found no difference in overall survival. However, we should not take any 
conclusions from this, because the 3 positive biopsies for mutated KRAS and EGFR belonged 
to very distinct patients: different stages at diagnosis (stage IA, IIIB and IV) and one of them 
had mesothelioma associated with adenocarcinoma and therefore the survival, in this case, 
was only 5 months.  
EGFR mutation is only carried by about 44 to 66% of female and non-smokers. 
Therefore in 2007 ALK rearrangements were identified and target therapeutic (crizotinib) was 
approved by FDA in April 2010. Patients with ALK rearrangement tend to be young, with a 
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younger median age of diagnosis comparing with EGFR mutations and there is a higher 
proportion of non-smokers or light smokers. The vast majority present with adenocarcinoma 
and have no sex preference for male or female.[20] However, in some studies, were 
encountered ALK positive patients older than 60 years. Thus, elderly patients should not 
generally be excluded from ALK testing. [21] In our study, ALK rearrangement was tested in 
11 cases; all relatively young patients. The ALK rearrangement was positive in a 57 years old 
female patient with a pleomorphic carcinoma with a component of adenocarcinoma, and in a 
smoking young male (28 years old) with adenocarcinoma. 
In the majority of centers, the diagnosis was made in advanced stages (IIIB and IV), 
and in this study the same was verified with 78.6% of cases; when that occurs symptoms are 
always present comparing with early stages where the patient is asymptomatic. [13] 
According with guidelines for patients with disease stage I or stage II surgery provides 
the best chance for cure. [15] In this study we verify that patients diagnosed in these stages 
(14.3%) where submitted to lobectomy and the three-year survival rate in these cases is quite 
high, 100 %. 
For patients with tumors in stage III, where there are different therapeutic options such 
as surgery, RT or CT it is required a multidisciplinary evaluation. To stage IIIA the 
therapeutic options should be organized according to the tumor location in view of the 
surgical resection.[15] In this research for this condition, it was found 1 patient that was 
submitted to surgery and adjuvant CT. In this case, for EGRF status we find WT and so no 
TKIs were administered. The survival was about 26 months.  
For patients in unresectable IIIA or IIIB stages without pleural or pericardial spilling, 
the choice of chemo-radiotherapy is superior to RT or CT isolated.[15] According to our data, 
in unresectable IIIA or IIIB stages, 44.4% of patients received CT plus RT concomitantly.  
Patients in stage IIIB, the tumor with T4, N0-1 (T4 tumors satellite lesions) corresponds to a 
group potentially curable with surgery. Resection is recommended, followed by CT. In this 
study only one patient in stage IIIB was submitted to surgery + CT and the survival was about 
14 months. 
For CT in NSCLC for advanced disease (patients in stage IIIB (N3 supraclavicular) or 
stage IV (M1a with pleural or pericardial), met analyzes have shown that when compared 
with best supportive therapy, CT resulted in increased survival of patients. For NSCLC in 
stage IV the goal of the therapy is to increase survival, control symptoms and to improve 
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quality of life. Therefore, 1st line CT recommended for patients with good performer status 
(PS) is a combination of platinum derivatives with other drugs of 3rd generation such as 
gemcitabine, vinorelbine, paclitaxel or docetaxel. For patients with non-squamous histology, 
in combination with pemetrexed, cisplatin demonstrated significant benefit in overall survival 
for patients with good condition. In our study and for advanced stages, 25 patients received a 
combination of platinum plus pemetrexed, what corresponds to 67.6 % of advanced stages. 
For patients with EGFR mutation it is also used the TKIs (gefitinib) in 1st line. [15] In our 
research about 7.1% received TKIs as a first line. Monotherapy with a 3rd generation drug, is 
a reasonable choice, with less iatrogenic effects and is an alternative for patients with PS 2 or 
elderly (age>70 years)  and in Portugal about 35- 40% of patients with lung cancer has more 
than 70 years old, significant comorbidities and high risk of toxicity for CT associations. So, 
it is used vinorelbine or gemcitabine. [15] In the study, 3 patients received oral vinorelbine as 
an alternative; 2 patients with 82 years old and 1 with 76 years old. 
The response to the 1st line CT is often short and progression may occur within 4-6 
months after finishing the 1st line therapy. Guidelines recommend docetaxel, pemetrexed or 
erlotinib in monotherapy after failure of a 1st CT regimen. Docetaxel is more effective than 
best supportive care, vinorelbine and Ifosfamide. Pemetrexed as an identical overall 
effectiveness compared to docetaxel, with significant lower toxicity and also greater efficacy 
and survival in non-squamous cell carcinomas. Erlotinib is indicated, for all histological 
types, after failure of at least one CT regimen. [15] In this study, after a 1st line, 28.9 % 
received a 2nd line with docetaxel or pemetrexed, about 26.7% received erlotinib. 
For 3rd line CT, erlotinib is the only approved agent for this disease without restriction 
phase. [15] In the research it was observed that 11.1 % received erlotinib as 3rd line. 
Despite the aggressive use of CT, the prognosis for patients with NSCLC advanced 
disease is poor with average survival of 9-12 months in stage IV. [15] 
Kaplan Meier curves (Fig.1-Fig.4) showed a low overall survival for this population, 
mostly in advanced stages as was expected. Comparing mutation status, the overall survival 
was quite higher in those with muted EGFR comparing with EGFR WT, and these results 
showed statistical significance. The tobacco exposure, as well as risk factors exposure also 
showed a tendency to aggravate the overall survival comparing with those who do not smoke. 
RT applied in stage IV is performed with palliative intent. In this analysis, patients in 
stage IV were in the majority of cases (30.6%) treated with RT for brain and for bone 
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metastases. For brain metastases, when it is single and ressecabale or partially ressecabale it is 
indicated surgery followed by holocraneane RT. [15] In this research one patient was 
submitted to metastasis resection resulting paresis. For multiple metastases it is recommended 
holocranean RT. About 13.9 % was submitted to RT for brain metastasis.  
 Bone metastases external radiation may be employed with the aim of preventing a 
pathological fracture, getting pain relief or avoid medullar compression. In these conditions 
22.2% were submitted to RT for bone metastases and in the remaining, the option was 
pharmacological therapeutics such as durogesic® or others related. 
 Concerning the most common patient’s complaints/intercurrences along the time for 
decrescendo order it was verified dyspnea (46.4%), cough (39.3%), pain from metastasized 
bone cancer (37.5%), chest pain (35.7%) and blood-tinged sputum (30.4%).   
After reuniting and analyzing all data we understand that in this research, we found a 
large heterogeneity for patients regarding histological, molecular and clinical features. When 
we identify histology and then mutation status, we can stand in different levels concerning the 
clinical process. Therefore, the majority of tested samples for the presence of mutation 
belonged to patients in advanced stages for the disease, were the surgery was not an option 
anymore and so it was fundamental to apply target methods to treat them. Testing for the 
presence of mutations, such as EGFR, KRAS or ALK rearrangement is fundamental to direct 
the treatment. Conventional CT allied to TKIs, when the EGRF is mutated, was the first line 
treatment for these patients. Those in early stages were much lesser, because as we already 
referred, the diagnosis is made much more frequently in advanced stages. The early stages are 
usually asymptomatic and the diagnosis is usually suspected in a routine examine, which 
means that it is an imagiologic finding. So, these patients were initially treated with surgery 
but then, in some phase of the disease it was verified a progression or a recidivating and 
therefore, mutation status was performed in order to offer more options to these patients, such 
as erlotinib in mutated EGFR or crizotinib for ALK rearrangement. In present time, testing for 
the mutations is a standard step performed at time of diagnosis to best direct the treatment in 
any phase of the disease. We understand that for EGFR and KRAS, this process is a routine 
but since 2009, when crizotinib was authorized by FDA, testing for ALK rearrangement is 
also important especially in patients with some especial features. The knowledge of the status 
mutation is fundamental to interview in good time for any stage of the 
development/progression of the disease.  
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In future studies it is relevant to continue to search and to test for targeted therapies. 
Obviously, a standard regimen is adequate but treatment “on series” is not adjusted for all the 
various features that can be finding among the molecular and clinical characterization of the 
bronchial pulmonary carcinoma. Further studies targeted on ALK fusion are extremely 
important because we realize that this affects a young part of population and therefore, 
offering them more effective therapies is crucial.  
At last, also some words for the importance of lung cancer screening. Various 
strategies for lung cancer screening were studied in order to achieve an earlier diagnosis, but 
despite some occasional benefits, no demonstrated advantages in terms of lower mortality 
were showed. With the publication of the results of the National Lung Screening Trial, which 
was supported by the National Cancer Institute, it was reached a new paradigm in relation to 
screening of these malignant tumors. The results showed that computerized tomography 
screening has found a decrease in mortality of 20% for lung cancer, in relation to the 
radiograph which, statistically, was very significant, and never before achieved, requiring 320 
computerized tomography scans to prevent 1 death due to lung cancer. The study, opened a 
window of opportunity for lung cancer screening at an early stage, but a few problems arise 
and are concerned with the high number of  lesions that need further investigation and then 
turn out to be benign, the emotional charge that this fact entails, the costs of screening, 
whether it should be extended to other groups of target populations, the fact that a negative 
computerized tomography scanning can motivate to continue to smoke, the possible risks in 
the long term radiation, the need to define how often the imaging studies should be obtained 
and how to monitor the follow-up of screened. There is a need to consolidate the benefits and 
characterize the possible risks of this approach, which should be based on centers with high 
quality imaging and where it is possible to have a multidisciplinary team that integrates 
imagiologists, pathologists, pulmonologists and thoracic surgeons to reach a consensus on the 
value of low-dose helical computerized tomography screening for populations at risk. [22] 
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ANNEX I – TNM Classification for Lung Cancer Staging 
ANNEX I – TNM Classification for Lung Cancer Staging 
Adapted from Lung Cancer Staging, American Joint Committee on Cancer, 7h edition, 2009 
